[
  {
    "ts": null,
    "headline": "AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE",
    "summary": "Amgen (NASDAQ:AMGN) will present at the 46th Annual TD Cowen Health Care Conference at 1:10 p.m. ET on Monday, March 2, 2026. Kave Niksefat, senior vice president of Global Marketing and Access at Amgen, and Justin Claeys, senior vice president of Finance at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.",
    "url": "https://finnhub.io/api/news?id=c79c0b3ad6928383c2da94542641a879fdf3dcaff7a1479029445eb606e09aaf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771966860,
      "headline": "AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE",
      "id": 139201639,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) will present at the 46th Annual TD Cowen Health Care Conference at 1:10 p.m. ET on Monday, March 2, 2026. Kave Niksefat, senior vice president of Global Marketing and Access at Amgen, and Justin Claeys, senior vice president of Finance at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.",
      "url": "https://finnhub.io/api/news?id=c79c0b3ad6928383c2da94542641a879fdf3dcaff7a1479029445eb606e09aaf"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics, Inc. (VKTX): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Viking Therapeutics, Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc.’s share was trading at $29.30 as of February 9th. Viking Therapeutics (VKTX) has emerged as a compelling scientific and strategic play in the obesity and metabolic therapy space, particularly following Novo Nordisk’s approval of the Wegovy® Pill, […]",
    "url": "https://finnhub.io/api/news?id=029b7dbdde0edbce7cc31f124b1535e3a85c362df061865139ed575048ff5a0b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771946275,
      "headline": "Viking Therapeutics, Inc. (VKTX): A Bull Case Theory",
      "id": 139197398,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Viking Therapeutics, Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc.’s share was trading at $29.30 as of February 9th. Viking Therapeutics (VKTX) has emerged as a compelling scientific and strategic play in the obesity and metabolic therapy space, particularly following Novo Nordisk’s approval of the Wegovy® Pill, […]",
      "url": "https://finnhub.io/api/news?id=029b7dbdde0edbce7cc31f124b1535e3a85c362df061865139ed575048ff5a0b"
    }
  },
  {
    "ts": null,
    "headline": "Amgen (AMGN) Valuation Check After Recent Share Price Strength And Analyst Fair Value Debate",
    "summary": "Amgen (AMGN) has drawn fresh attention after recent trading left the shares at $379.42, capping a period in which returns over the past month and the past three months have both been positive. See our latest analysis for Amgen. The latest move to $379.42 comes on top of a 10.06% 1 month share price return and a 15.80% year to date share price return. The 1 year total shareholder return of 26.35% and 5 year total shareholder return of 95.51% point to momentum that has built steadily over...",
    "url": "https://finnhub.io/api/news?id=9d15ffdcbc3d12056a5f33366a02dceabb9f248eaaed76bf217ca5e93d8d77ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771924391,
      "headline": "Amgen (AMGN) Valuation Check After Recent Share Price Strength And Analyst Fair Value Debate",
      "id": 139192457,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) has drawn fresh attention after recent trading left the shares at $379.42, capping a period in which returns over the past month and the past three months have both been positive. See our latest analysis for Amgen. The latest move to $379.42 comes on top of a 10.06% 1 month share price return and a 15.80% year to date share price return. The 1 year total shareholder return of 26.35% and 5 year total shareholder return of 95.51% point to momentum that has built steadily over...",
      "url": "https://finnhub.io/api/news?id=9d15ffdcbc3d12056a5f33366a02dceabb9f248eaaed76bf217ca5e93d8d77ca"
    }
  }
]